Literature DB >> 3611252

Comparison of high-selectivity gas chromatographic methods, including column switching, for the determination of felodipine in plasma.

M Ahnoff, M Ervik, L Johansson.   

Abstract

The selectivity required for the determination of low concentrations of felodipine in plasma was achieved by either mass-selective detection, optimization of stationary phase selectivity or column-switching gas chromatography (GC) with a dual-oven chromatograph, the latter two with electron-capture detection. The three approaches were evaluated in terms of selectivity, detectability, precision and suitability for routine applications with automated injection. Using mass-selective detection, the detectability in plasma samples was limited by the performance of the mass spectrometer. The detection limit (signal-to-noise ratio = 3) was 4.7 pmol (1.8 pg) of felodipine. Pre-concentration of extracts permitted quantitation in plasma down to 0.2 nmol/1. Using electron-capture detection, the detectability was determined by the selectivity and bleeding characteristics of the columns. For single-column separation, a 35% phenyl phase was selected. The detection limit was 3.0 fmol (1.2 pg). The limit of quantitation in plasma was 1 nmol/1. In column-switching GC, bleeding products from the first column will separate on the second column and may interfere in separations for trace analysis. Bleeding products from a 50% phenyl phase (DB-17) were characterised by GC-mass spectrometry. With a dual-column system, employing a DB-17 (50% phenyl) column for selective introduction on to a CP-Sil 5 (0% phenyl) column, the signal-to-noise ratio was limited by the low-bleeding second column, provided that the bleeding products from the first column were adequately separated from felodipine. The detection limit in this instance was significantly lower 0.35 fmol (0.13 pg). Direct injection of plasma extracts permitted quantitation down to 0.4 nmol/l. All three methods were well suited for use with autosamplers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3611252     DOI: 10.1016/s0021-9673(01)83809-7

Source DB:  PubMed          Journal:  J Chromatogr


  9 in total

1.  A population study of the pharmacokinetics of felodipine.

Authors:  E Blychert; B Edgar; D Elmfeldt; T Hedner
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

2.  Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.

Authors:  E Blychert; K Wingstrand; B Edgar; K Lidman
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

3.  Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects.

Authors:  S Landahl; B Edgar; M Gabrielsson; M Larsson; B Lernfelt; P Lundborg; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

Review 4.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

5.  Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure.

Authors:  P H Dunselman; B Edgar; A H Scaf; C E Kuntze; H Wesseling
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

6.  Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients.

Authors:  A H Scaf; P H Dunselman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

7.  Pharmacokinetics of felodipine in patients with impaired renal function.

Authors:  B Edgar; C G Regårdh; P O Attman; M Aurell; H Herlitz; G Johnsson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

8.  Felodipine in the treatment of patients with severe hypertension and impaired renal function.

Authors:  R Larsson; M K Lindsjö; B Danielsson; U Bengtsson; J H Hardlund; P A Sjöström; D Elmfeldt; L Moberg
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

9.  Pharmacokinetics of felodipine in patients with liver disease.

Authors:  C G Regårdh; B Edgar; R Olsson; M Kendall; P Collste; C Shansky
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.